Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novavax, FUJIFILM Initiate Large Scale Mfg. of COVID-19 Vax Candidate | Contract Pharma
Breaking News

Novavax, FUJIFILM Initiate Large Scale Mfg. of COVID-19 Vax Candidate

FUJIFILM to manufacture bulk drug substance for NVX-CoV2373 from its site in Morrisville, NC for Phase III trial.

Novavax, Inc. and FUJIFILM Diosynth Biotechnologies (FDB), a contract development and manufacturing organization for biologics, viral vaccines and gene therapies, entered an agreement to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, NC has begun production of the first batch of NVX-CoV2373. 

This agreement falls under Novavax’ recent $1.6 billion award by the federal government as part of the Operation Warp Speed (OWS) that aims to deliver millions of doses of a vaccine for COVID-19 to the U.S. population. The OWS funding is being used by Novavax to complete late-stage clinical development, including a Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX–CoV2373 beginning as early as late 2020.

NVX-CoV2373 consists of a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ Matrix–M adjuvant.  The batches produced at the FDB site in North Carolina will be utilized in a future Phase 3 trial of up to 30,000 subjects, which is expected to begin in the fall of 2020.

Novavax expects preliminary immunogenicity and safety results from a Phase 1/2 trial of NVX-CoV2373 in 130 healthy participants 18 to 59 years of age during the first week of August. The Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin shortly thereafter. The Phase 1/2 clinical trial is being supported by an up-to $388 million funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters